Attendees fed up with venue, prices call to move JPM out of SF by Conor Hale Tuesday, January 15, 2019 While the high cost of living in San Francisco has famously grabbed headlines, the costs of simply meeting there are becoming untenable for some.
Deciphera CBO Morl talks lines of therapy for kinase inhibitor ripretinib by Amirah Al Idrus Friday, January 11, 2019 Deciphera aims to get ripretinib approved first as a fourth- and second-line treatment for GIST, but is not looking for a first-line approval.
Orchard's 2019: Pipeline progress, new $90M manufacturing site by Amirah Al Idrus Friday, January 11, 2019 Armed with a total of $375 million raised, Orchard will build its own manufacturing site in California, to start running in 2021.
M&A, IPOs and VC raises: Biotech, medtech execs look to 2019 by Amirah Al Idrus, Conor Hale, Ben Adams Friday, January 11, 2019 What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.
ResMed and Propeller Health announce new Walgreens partnership by Conor Hale Thursday, January 10, 2019 At JPM, Propeller Health closed its $225 million buyout with ResMed and launched a partnership with Walgreens for in-app prescription refills.
Aimmune’s peanut allergy drug outruns FDA shutdown; other programs not so lucky by Amirah Al Idrus Thursday, January 10, 2019 The FDA shutdown is holding up human trials for Aimmune's egg allergy program and may delay approval for its oral immunotherapy for peanut allergy.
Rewiring R&D: The FierceBiotech JPM 2019 breakfast debate by Ben Adams Wednesday, January 9, 2019 We certainly like to offer a full breakfast here at FierceBiotech, especially at the J.P. Morgan Healthcare Conference here in San Francisco.
New year, new Axovant: CEO on the company's gene therapy pivot by Amirah Al Idrus Wednesday, January 9, 2019 Since Pavan Cheruvu took Axovant’s helm in February 2018, the company has been plugging away at becoming a gene therapy player.
With new data, new targets, Tmunity to gather steam in 2019 by Amirah Al Idrus Wednesday, January 9, 2019 In 2019, Tmunity hopes to share data from its lead T cell programs and announce new solid tumor targets.
Pear nets $64M, launches Rx app for opioid use disorder by Conor Hale Wednesday, January 9, 2019 Pear Therapeutics posted $64 million in new funding on the heels of an FDA clearance for its prescription software to treat opioid addiction.
